QYUNS-B(02509): Long-acting dual antibody QX027N receives two clinical trial implicit approvals.

QYUNS-B (02509) announced that the company's independently developed long-acting dual-target QX027N injection has obtained clinical trial implicit approval from the Drug Evaluation Center of the National Medical Products Administration (Acceptance No.: CXSL2500757, CXSL2500758), and is intended to be used for the treatment of asthma and atopic dermatitis. The clinical approval of this candidate drug marks the company's innovative dual-target matrix in the field of autoimmune and allergic diseases officially entering the clinical stage. QX027N is an important achievement in the company's development of bispecific antibodies, indicating further progress in the company's collaborative layout in the respiratory and skin disease fields. Faced with the urgent clinical needs of hundreds of millions of asthma and atopic dermatitis patients worldwide, the company will continue to advance the research and clinical translation of innovative therapies, providing patients with more effective, safer, and more convenient treatment options.